文献速递睡眠障碍心境障碍

基于生活史与情感人格特质识别的失眠障碍亚型

Insomnia disorder subtypes derived from life history and traits of affect and personality.
PubMed 文献 · Lancet Psychiatry · 2019-01-07

亚型在发育轨迹、治疗反应、脑电生物标志物及抑郁风险(组间差异最高达5倍)上存在差异,提示分型具有临床相关性。

要点

  • 数据驱动法识别5种失眠障碍亚型,独立样本重复验证成功。
  • 亚型间抑郁风险差异最高达5倍,治疗反应和脑电标志物亦不同。

核心结论

  • 高维数据驱动的失眠障碍分型可减少异质性,有助于识别病因、开发个体化治疗及筛选抑郁高风险患者。

研究设计与样本

  • 研究从荷兰睡眠登记库招募18岁及以上参与者,使用34份选定问卷在线追踪特质、睡眠、生活事件和健康史,采用潜在类别分析识别亚型。
  • 在第二个非重叠队列(251名新参与者)中重复验证亚型,并评估数年随访的个体内稳定性。
  • 对亚型的临床效度进行广泛测试,包括睡眠抱怨发展、共病(含抑郁)及苯二氮䓬类药物反应;在两种亚型中还评估了脑电生物标志物和认知行为治疗效果。
  • 构建简明亚型问卷并在第二非重叠队列中验证。

主要发现

  • 4322名参与者中2224人(51%)为可能失眠障碍(ISI评分至少10),2098人(49%)ISI评分较低作为对照组。
  • 潜在类别分析识别出5种失眠障碍亚型:高度痛苦型、中度痛苦但奖赏敏感型、中度痛苦且奖赏不敏感型、轻度痛苦高反应型、轻度痛苦低反应型。
  • 在251名新参与者的重复样本中,5种亚型同样被识别为最优。

关键数值与推荐

  • 可能失眠障碍定义为ISI评分至少10。
  • 亚型间抑郁风险差异最高达5倍。

临床怎么用

  • 失眠障碍可分5种亚型,亚型分类稳定且与治疗反应、抑郁风险相关,有助于个体化治疗和抑郁预防试验筛选。
  • 简明亚型问卷经独立样本验证,可促进分型在临床中的实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Insomnia disorder is the second most prevalent mental disorder, and it is a primary risk factor for depression. Inconsistent clinical and biomarker findings in patients with insomnia disorder suggest that heterogeneity exists and that subtypes of this disease remain unrecognised. Previous top-down proposed subtypes in nosologies have had insufficient validity. In this large-scale study, we aimed to reveal robust subtypes of insomnia disorder by use of data-driven analyses on a multidimensional set of biologically based traits. METHODS: In this series of studies, we recruited participants from the Netherlands Sleep Registry, a database of volunteers aged 18 years or older, who we followed up online to survey traits, sleep, life events, and health history with 34 selected questionnaires of which participants completed at least one. We identified insomnia disorder subtypes by use of latent class analyses. We evaluated the value of our identified subtypes of insomnia disorder by use of a second, non-overlapping cohort who were recruited through a newsletter that was emailed to a new sample of Netherlands Sleep Registry participants, and by assessment of within-subject stability over several years of follow-up. We extensively tested the clinical validity of these subtypes for the development of sleep complaints, comorbidities (including depression), and response to benzodiazepines; in two subtypes of insomnia disorder, we also assessed the clinical relevance of these subtypes by use of an electroencephalogram biomarker and the effectiveness of cognitive behavioural therapy. To facilitate implementation, we subsequently constructed a concise subtype questionnaire and we validated this questionnaire in the second, non-overlapping cohort. FINDINGS: 4322 Netherlands Sleep Registry participants completed at least one of the selected questionnaires, a demographic questionnaire, and an assessment of their Insomnia Severity Index (ISI) between March 2, 2010, and Oct 28, 2016. 2224 (51%) participants had probable insomnia disorder, defined as an ISI score of at least 10, and 2098 (49%) participants with a lower ISI score served as a control group. With a latent class analysis of the questionnaire responses of 2224 participants, we identified five novel insomnia disorder subtypes: highly distressed, moderately distressed but reward sensitive (ie, with intact responses to pleasurable emotions), moderately distressed and reward insensitive, slightly distressed with high reactivity (to their environment and life events), and slightly distressed with low reactivity. In a second, non-overlapping replication sample of 251 new participants who were assessed between June 12, 2017, and Nov 26, 2017, five subtypes were also identified to be optimal. In both the development sample and replication sample, each participant was classified as having only one subtype with high posterior probability (0·91-1·00). In 215 of the original sample of 2224 participants with insomnia who were reassessed 4·8 (SD 1·6) years later (between April 13, 2017, and June 21, 2017), the probability of maintaining their original subtype was 0·87, indicating a high stability of the classification. We found differences between the identified subtypes in developmental trajectories, response to treatment, the presence of an electroencephalogram biomarker, and the risk of depression that was up to five times different between groups, which indicated a clinical relevance of these subtypes. INTERPRETATION: High-dimensional data-driven subtyping of people with insomnia has addressed an unmet need to reduce the heterogeneity of insomnia disorder. Subtyping facilitates identification of the underlying causes of insomnia, development of personalised treatments, and selection of patients with the highest risk of depression for inclusion in trials regarding prevention of depression. FUNDING: European Research Council and Netherlands Organization for Scientific Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Blanken TF, Benjamins JS, Borsboom D, et al. Insomnia disorder subtypes derived from life history and traits of affect and personality. Lancet Psychiatry. 2019. PMID: 30630691. doi:10.1016/S2215-0366(18)30464-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。